Impact of Repeated Non‐Fatal Infections on Quality of Life and Graft Function in ABO‐Incompatible Kidney Transplants
Transplant Infectious Disease · 2025
DOI: 10.1111/tid.70084 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant Infectious Disease, 2025. Verfasst von Federica Bocchi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, Bern, Switzerland. Hauptthemen laut MEDLINE: Kidney Transplantation, ABO Blood-Group System, Blood Group Incompatibility, Quality of Life. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Kidney transplantation (KT) is the preferred treatment for kidney failure, with living donor KT (LDKT) offering better outcomes and improved quality of life (QOL) than deceased donor KT. ABO incompatibility (ABOi) once restricted LDKT, but desensitization protocols now enable ABOi LDKT, expanding the donor pool with favorable outcomes. However, added risks of ABOi remain debated. We examined the impact of repeated infections on graft loss and death in both ABO‐compatible (ABOc) and ABOi LDKT recipients.
Methods
Retrospective, nationwide Swiss Transplant Cohort Study from May 2008 to December 2022, including all ABOi LDKT patients. Clinically relevant infections (viral, bacterial, fungal, and parasitic) were analyzed as repeated adverse events.
Results
Among 227 ABOi LDKT and 1172 ABOc recipients, 13% (183/1399) had ≥ 2 significant infections within the first 6 months. ABOi was independently associated to a higher infection risk (HR 1.21, 95% CI 1.10–1.34, p < 0.001). Patients with early recurrent infections were older, often female, and had ABOi LDKT. Patients with ≥ 2 infections faced increased risks of graft loss, lower eGFR, and reduced QOL.
Conclusion
ABOi LDKT patients face a higher risk of recurrent infections, especially within 6 months post‐KT, associated with reduced allograft function and lower QOL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, Bern, Switzerland.
- Department of Nephrology and Dialysis, Assistance Publique Hôpitaux de Paris, Hôpital Tenon, Paris, France.
- Clinic of Nephrology, Transplantation Medicine, Kantonspital St. Gallen, St. Gallen, Switzerland.
- Transplantation Center, Department of Medicine, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
- Department of Nephrology and Hypertension, HUG, Geneva University Hospital, Geneva, Switzerland.
- Department of Infectious Diseases, Inselspital, Bern University Hospital, Bern, Switzerland.
ORCID-Profile: Federica Bocchi, Dela Golshayan, Cédric Hirzel, Thomas Schachtner, Daniel Sidler
Zitieren
APA
Bocchi, F., Binet, I., Golshayan, D., Haidar, F., Hirzel, C., Müller, T., Schachtner, T., & Sidler, D. (2025). Impact of Repeated Non‐Fatal Infections on Quality of Life and Graft Function in ABO‐Incompatible Kidney Transplants. Transplant Infectious Disease. https://doi.org/10.1111/tid.70084
Vancouver
Bocchi F, Binet I, Golshayan D, Haidar F, Hirzel C, Müller T, et al. Impact of Repeated Non‐Fatal Infections on Quality of Life and Graft Function in ABO‐Incompatible Kidney Transplants. Transplant Infectious Disease. 2025. doi:10.1111/tid.70084
BibTeX
@article{Bocchi2025,
author = {Bocchi, Federica and Binet, Isabelle and Golshayan, Dela and Haidar, Fadi and Hirzel, Cédric and Müller, Thomas and Schachtner, Thomas and Sidler, Daniel},
title = {Impact of Repeated Non‐Fatal Infections on Quality of Life and Graft Function in ABO‐Incompatible Kidney Transplants},
journal = {Transplant Infectious Disease},
year = {2025},
doi = {10.1111/tid.70084}
}
EUVIMED